Shop Now Contact

Human GLP-1 Receptor Agonist (Semaglutide Biosimilar)

Cat # Size Price Quantity
5057011 mg$190
5057025 mg$480
50570320 mg$1100

  Bulk/Custom

Product Details

CloneSemaglutide
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionSemaglutide Biosimilar
IsotypeNA
Regulatory StatusRUO
ClonalityRecombinant
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsGLP1
Target NameGLP-1 receptor, GLP1R, GLP-1 Receptor Agonists
Antibody TypeRecombinant
Research AreasMetabolism
See All FormatsClone Semaglutide

Background Information

Semaglutide is a synthetic peptide analogue of the human glucagon-like peptide-1 (GLP-1) hormone, designed to activate GLP-1 receptors with enhanced stability and a prolonged half-life compared to the native peptide. Structurally, Semaglutide is a 31-amino acid polypeptide that closely resembles endogenous GLP-1, differing by strategic amino acid substitutions and chemical modifications that improve resistance to enzymatic degradation and extend its duration of action. Its molecular weight is approximately 4.1 kilodaltons (kDa). These structural changes include the substitution of alanine with α-aminoisobutyric acid at position 8, which confers resistance to cleavage by dipeptidyl peptidase-4 (DPP-4), and the attachment of a C18 fatty diacid chain via a glutamic acid spacer at lysine 26, enabling reversible binding to albumin in circulation.

The molecular design of Semaglutide ensures a balance between receptor activation and molecular stability. The peptide adopts a helical conformation similar to native GLP-1 when bound to the GLP-1 receptor, a class B G protein-coupled receptor (GPCR). The N-terminal region interacts with the receptor’s transmembrane domain, initiating receptor activation and intracellular signaling. This activation triggers the adenylate cyclase pathway, leading to cyclic adenosine monophosphate (cAMP) accumulation, protein kinase A (PKA) activation, and modulation of downstream metabolic enzymes. Additionally, the C-terminal acylation with the long-chain fatty diacid anchors the molecule to plasma albumin, reducing renal clearance and protecting it from proteolytic degradation, significantly extending its half-life.

Functionally, Semaglutide mimics the biological activity of endogenous GLP-1, promoting sustained receptor signaling in experimental models of glucose metabolism and energy balance. Its prolonged receptor occupancy and systemic stability make it a useful model for studying GPCR kinetics, peptide–receptor binding dynamics, and the role of structural modifications in peptide pharmacology.

Data Sheets

Human GLP-1 Receptor Agonist (Semaglutide Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.